MCRB Historical PE Ratio Notes

— Seres Therapeutics ("MCRB") is a leading microbiome therapeutics company focused on developing transformative biological drugs using live bacterial consortia to treat infectious, inflammatory, and other serious diseases. Their most advanced product, VOWST™ (formerly SER-109), received FDA approval as the first orally administered microbiome therapy for preventing recurrent C. difficile infection, reflecting their innovative position in biotechnology. When analyzing MCRB’s historical P/E (price-to-earnings) ratio, it’s vital to consider that the company, for most of its existence, operated at a pre-commercial, development-stage status with little or negative earnings, which typically results in either very high or non-meaningful P/E ratios. This means traditional valuation metrics like P/E have often been less relevant, as investors priced MCRB based mainly on future growth potential & pipeline prospects rather than historical profits. Periods when the company reported considerable net losses or minimal revenues, especially pre-approval, generally led to negative or undefined P/E ratios. Only recently—post-commercial launch of VOWST—might there be periods where P/E ratios become more meaningful, pending sustained positive earnings. Understanding this context is crucial for interpreting any historical price, earnings, and P/E ratio data you'll encounter for MCRB.

On this page we presented the Seres Therapeutics Historical PE Ratio information for Seres Therapeutics' stock. The average MCRB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 2.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average MCRB historical PE based on this TTM earnings result method is 14.6. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this MCRB historical PE result, against the recent PE: when this page was posted on 3/13/2026, the most recent closing price for MCRB had been 8.63, and the most recent quarterly earnings result, annualized, was 3.76. Meanwhile, the most recent TTM earnings summed to 0.66. From these numbers, we calculate the recent MCRB PE on 3/13/2026 based on annualized quarterly EPS was 2.3. Based on MCRB's history, that recent PE is low relative to the historical average, with the recent PE 8.0% lower than the historical average PE across our data set for Seres Therapeutics. Looking at the recent MCRB PE on 3/13/2026 based on TTM EPS, we calculate the ratio at 13.1. Based on MCRB's history, that recent PE is low relative to the historical average, with the recent PE 10.3% lower than the average PE across our Seres Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on MCRB or any other given stock, valuation analysis for MCRB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Seres Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for MCRB. Thanks for visiting, and the next time you need to research MCRB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.